CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
with immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC) resistant to immune checkpoint inhibitors. The pr...
Phase 1
Montréal, Quebec, Canada
a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...
Phase 2
Montréal, Canada and 48 other locations
and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer...
Phase 2
Montreal, Canada and 46 other locations
to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previous...
Phase 3
Montreal, Quebec, Canada and 69 other locations
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
Montréal, Quebec, Canada and 209 other locations
This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer...
Phase 3
Montreal, Quebec, Canada and 140 other locations
resectable, early-stage non-small cell lung cancer....
Phase 2
Montreal, Quebec, Canada and 94 other locations
combination with pembrolizumab in participants with non-small cell lung cancer (NSCLC).Each treatment cycle lasts 21 days. Particip...
Phase 1, Phase 2
Montréal, Quebec, Canada and 12 other locations
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the ...
Phase 3
Montréal, Quebec, Canada and 238 other locations
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as...
Phase 3
Montreal, Quebec, Canada and 182 other locations
Clinical trials
Research sites
Resources
Legal